• Former Executive Vice President, Chief Scientific Officer, Bristol-Myers Squibb
B.S., M.S. (1973) – Purdue University, Indiana (Industrial Engineering)
Ph.D. (1977) – Purdue University, Indiana (Engineering)
M.D. (1981 )- University of Chicago, Illinois
Elliott Sigal, M.D., Ph.D. is a former Executive Vice President and Director of Bristol-Myers Squibb. He served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma Transformation Strategy of the company which is fully dedicated to innovative therapies for unmet medical needs. He has been instrumental in increasing R&D productivity, acquiring external innovation, and helping to develop the company’s strategy in biologics.
Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology.
Dr. Sigal has been in leadership positions at Bristol-Myers Squibb in both Research and in Development. He started as Vice President of the newly created department of Applied Genomics in 1997. In 1999, he became Senior Vice President for Early Discovery and Applied Technology. He was named Head of Drug Discovery & Exploratory Development in 2001, Head of Development in 2002 and Head of R&D in 2004.
Dr. Sigal has more than 25 years of combined experience in medicine, research and management. In 1992 he joined the pharmaceutical company Syntex and held positions of increasing responsibility in drug discovery. In 1995 Dr. Sigal joined the genomics firm Mercator Genetics as Vice President of Research and Development and later served as CEO. While there he provided the research leadership that resulted in the discovery of the gene for hemochromatosis, a common disorder that leads to iron overload, diabetes and liver disease.
Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). He received his research training at the Cardiovascular Research Institute at UCSF. Dr. Sigal served on the faculty of the UCSF Department of Medicine from 1988 to 1992. Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Dr. Sigal serves as a board member for the Mead Johnson Nutrition Company and the Melanoma Research Alliance. He also serves as a senior advisor to the healthcare team of NEA and consults for select biotechnology companies.